Clinical Trials
43 trialsNCT05599048 2026-05-27
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
University of California, San Francisco
Phase 1/2 Recruiting
NCT05170958 2026-05-15
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT05038150 2026-05-05
Study of SGN1 in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT05103345 2026-05-05
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT07298772 2026-05-01
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT07300943 2026-05-01
Study in Advanced Solid Tumor Patients
Callio Therapeutics
Phase 1/2 Recruiting
NCT06833008 2026-04-30
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT05451602 2026-04-28
HEC169096 in Participants With Advanced Solid Tumors
Sunshine Lake Pharma Co., Ltd.
Phase 1/2 Recruiting
NCT06635785 2026-04-09
BiPAVE-001
OncoC4, Inc.
Phase 1/2 Recruiting
NCT06911827 2026-04-07
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT06953323 2026-03-27
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06253130 2026-03-23
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Eikon Therapeutics
Phase 1/2 Recruiting
NCT05443126 2026-02-03
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Ellipses Pharma
Phase 1/2 Recruiting
NCT05584800 2026-01-05
Study of ZGGS18 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT06938880 2026-01-05
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT07124117 2026-01-05
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
OBI Pharma, Inc
Phase 1/2 Recruiting
NCT06825494 2025-12-18
Clinical Studies for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT07256782 2025-12-01
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT07083323 2025-11-25
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT05434234 2025-11-10
A Study of YL201 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT06682780 2025-09-25
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT06187402 2025-09-09
A Study of LM-24C5 For Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT05684965 2025-09-08
XTX301 in Patients With Advanced Solid Tumors
Xilio Development, Inc.
Phase 1/2 Recruiting
NCT05761223 2025-08-17
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
1ST Biotherapeutics, Inc.
Phase 1/2 Recruiting
NCT05978102 2025-07-23
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1/2 Recruiting
NCT06277219 2025-07-08
LIGHTSPEED-1
Latticon Antibody Therapeutics, Inc
Phase 1/2 Recruiting
NCT05263960 2025-05-04
A Study of CM350 in Patients With Advanced Solid Tumors
Keymed Biosciences Co.Ltd
Phase 1/2 Recruiting
NCT06669975 2025-04-25
A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
AP Biosciences Inc.
Phase 1/2 Recruiting
NCT06431243 2025-04-10
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2 Recruiting
NCT05142423 2025-03-12
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Akeso
Phase 1/2 Recruiting
NCT05487170 2025-03-04
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Ranok Therapuetics Co. Ltd.
Phase 1/2 Recruiting
NCT06173219 2025-02-27
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
China-Japan Friendship Hospital
Phase 1/2 Recruiting
NCT06038396 2025-01-29
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT05205850 2025-01-27
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT05417321 2025-01-03
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT06410703 2024-10-31
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Canwell Biotech Limited
Phase 1/2 Recruiting
NCT05367778 2024-09-19
Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT06525298 2024-09-19
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Eisbach Bio GmbH
Phase 1/2 Recruiting
NCT04282031 2024-08-07
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Beta Pharma (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT06081907 2024-05-30
Promise
Hunan Province Tumor Hospital
Phase 1/2 Recruiting
NCT05525247 2023-09-21
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
Selecxine
Phase 1/2 Recruiting
NCT05204862 2023-04-03
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
TiumBio Co., Ltd.
Phase 1/2 Recruiting